

# Antimicrobial Stewardship Matters

Antimicrobial Stewardship | September 2025

---

## Antibiotics: Consider the Risks

### At a Glance:



Think twice before prescribing an antibiotic and ensure your patient is counseled about the potential harms:

- Antibiotics are a leading cause of adverse drug reaction – and each day increases the risk.
- Any antibiotic carries a risk of *C. difficile* infection (CDI), and is higher than you think.
- Associations exist between antibiotic use and the development of chronic disease.

### First, Do No Harm

While antibiotics have become a cornerstone of modern medicine, their harms extend well beyond antibiotic resistance. With 30 per cent of antibiotic use considered inappropriate,<sup>1</sup> “better safe than sorry” should be replaced with a clear assessment of the potential for harm.

### Adverse Drug Reaction (ADR)

Antibiotics are the most common cause of ADR leading to emergency department attendance in children, and the fourth most common in adults.<sup>2</sup>

Half of all hospitalized patients receive an antibiotic, with a fifth experiencing an ADR.<sup>3</sup> Each day of therapy increases the odds of an ADR by four per cent.

---

## *Clostridioides difficile*

All antibiotics predispose to CDI. The risk increases with:

- Broader spectrum antibiotics
- Longer duration - **each additional day** is associated with an 8-13% increase in odds of developing CDI.<sup>5</sup>

Adjusted risk ratio of CDI versus no antibiotics:

- Cefixime: **4.3**
- Amoxicillin-Clavulanate: **2.4**
- Azithromycin: **2.2**
- Ciprofloxacin: **1.9**

## Long Term Effects

Research is increasingly associating early life antibiotic use with:

- Asthma, Eczema, Allergic Rhinitis<sup>7</sup>
- Obesity<sup>8</sup>
- Inflammatory Bowel Disease, Celiac Disease<sup>7</sup>
- Juvenile Idiopathic Arthritis<sup>9</sup>

With the broad impact our microbiome has on our health, the decision to provide antibiotics should not be made lightly.



In addition to the common gastrointestinal effects and *C. difficile* risk, below are a few additional antibiotic-specific harms to be aware of for a select group of antibiotics:

| Antibiotic                    | Serious Harms                                                                                                                                           | Mitigating Measures                                                                                                                                                                                                                                              |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Doxycycline                   | Hypersensitivity or serum sickness reaction<br>Esophagitis<br>Phototoxicity                                                                             | <ul style="list-style-type: none"> <li>• Counsel patient of signs</li> <li>• Take with full glass of water</li> <li>• Sun protection measures</li> </ul>                                                                                                         |
| Linezolid                     | Myelosuppression<br>Lactic acidosis<br>Peripheral/optic neuropathy                                                                                      | <ul style="list-style-type: none"> <li>• Monitor CBC and lactate</li> <li>• Counsel patient of symptoms, assess if present during follow up</li> </ul>                                                                                                           |
| Macrolides                    | Cardiac arrhythmia<br>Hearing loss                                                                                                                      | <ul style="list-style-type: none"> <li>• Use with caution or avoid in those with known QT prolongation or QT prolonging medications</li> <li>• Counsel patient, assess if present during follow up</li> </ul>                                                    |
| Metronidazole                 | Seizures<br>Peripheral neuropathy (prolonged use)                                                                                                       | <ul style="list-style-type: none"> <li>• In those with known seizure disorder, ensure pharmacologic and nonpharmacologic preventative measures are optimized</li> <li>• Counsel patient, assess if present during follow up</li> </ul>                           |
| Nitrofurantoin                | Pulmonary toxicity (irreversible)<br>Drug-induced liver injury<br>Anemia (aplastic or hemolytic)<br>Peripheral neuropathy                               | <ul style="list-style-type: none"> <li>• Avoid prolonged use, counsel patient and assess if signs or symptoms present during follow up</li> </ul>                                                                                                                |
| Fluoroquinolones              | Tendonitis and Achilles tendon rupture<br>Increased risk of abdominal aorta rupture<br>Dysglycemia<br>Psychiatric disturbances<br>Peripheral neuropathy | <ul style="list-style-type: none"> <li>• Use with caution in those &gt;60 years of age, current corticosteroid use, inadequately controlled diabetes, or known mental health disorders</li> <li>• Counsel patient, assess if present during follow up</li> </ul> |
| Trimethoprim-sulfamethoxazole | Hyperkalemia<br>Hypersensitivity reactions (eg. Severe cutaneous drug reactions, interstitial nephritis, vasculitis etc)                                | <ul style="list-style-type: none"> <li>• Monitor potassium in those with impaired renal function or current use of medications impairing renal excretion of potassium</li> <li>• Counsel patient of signs, assess if present during follow up.</li> </ul>        |

Adapted from Mohsen et al. Can Fam Physician. 2020;66(9):651-659.



## Missed an issue?

Explore our full newsletter collection online:  
[Antimicrobial Stewardship Matters](#)



---

# References

1. Hersh AL, King LM, Shapiro DJ, Hicks LA, Fleming-Dutra KE. Unnecessary Antibiotic Prescribing in US Ambulatory Care Settings, 2010–2015. *Clin Infect Dis*. 2021;72(1):133-137. doi:10.1093/cid/ciaa667
2. Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. US Emergency Department Visits Attributed to Medication Harms, 2017–2019. *JAMA*. 2021;326(13):1299. doi:10.1001/jama.2021.13844
3. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. *JAMA Intern Med*. 2017;177(9):1308. doi:10.1001/jamainternmed.2017.1938
4. Curran J, Lo J, Leung V, et al. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. *Clin Microbiol Infect*. 2022;28(4):479-490. doi:10.1016/j.cmi.2021.10.022
5. Gilboa M, Regev-Yochay G, Meltzer E, et al. Antibiotic Use and the Risk of Hospital-Onset *Clostridioides Difficile* Infection. *JAMA Netw Open*. 2025;8(8):e2525252. doi:10.1001/jamanetworkopen.2025.25252
6. Brown KA, Langford B, Schwartz KL, Diong C, Garber G, Daneman N. Antibiotic Prescribing Choices and Their Comparative *C. Difficile* Infection Risks: A Longitudinal Case-Cohort Study. *Clin Infect Dis*. 2021;72(5):836-844. doi:10.1093/cid/ciaa124
7. Aversa Z, Atkinson EJ, Schafer MJ, et al. Association of Infant Antibiotic Exposure With Childhood Health Outcomes. *Mayo Clin Proc*. 2021;96(1):66-77. doi:10.1016/j.mayocp.2020.07.019
8. Meng X, Zhu Y, Di H, et al. Dose-response association of early-life antibiotic exposure and subsequent overweight or obesity in children: A meta-analysis of prospective studies. *Obes Rev*. 2021;22(11):e13321. doi:10.1111/obr.13321
9. Hestetun S, Andersen S, Sanner H, Størdal K. Antibiotic exposure in prenatal and early life and risk of juvenile idiopathic arthritis: a nationwide register-based cohort study. *RMD Open*. 2023;9(3):e003333. doi:10.1136/rmdopen-2023-003333
10. Mohsen S, Mb JAD, Frcpc RS. Update on the adverse effects of antimicrobial therapies in community practice. *Can Fam Physician*. 2020;66(9):651-659.

